These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23402725)

  • 21. Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention.
    Ono T; Kaikita K; Hokimoto S; Iwashita S; Yamamoto K; Miyazaki Y; Horio E; Sato K; Tsujita K; Abe T; Deguchi M; Tayama S; Sumida H; Sugiyama S; Yamabe H; Nakamura S; Nakagawa K; Ogawa H
    Thromb Res; 2011 Dec; 128(6):e130-6. PubMed ID: 21862109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents.
    Oh IY; Park KW; Kang SH; Park JJ; Na SH; Kang HJ; Koo BK; Jeong YH; Hwang JY; Kwak CH; Park Y; Hwang SJ; Ko YG; Shin DJ; Jang Y; Kim HS
    Heart; 2012 Jan; 98(2):139-44. PubMed ID: 21700758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of CYP2C19 polymorphism and smoking on response to clopidogrel in patients with stable coronary artery disease.
    Liu XL; Wang ZJ; Yang Q; Ge HL; Gao F; Liu YY; Shi DM; Zhao YX; Zhou YJ
    Chin Med J (Engl); 2010 Nov; 123(22):3178-83. PubMed ID: 21163112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Searching for the ceiling: new reflections on the disposition and metabolism of clopidogrel.
    Kleiman NS
    JACC Cardiovasc Interv; 2008 Dec; 1(6):628-30. PubMed ID: 19463376
    [No Abstract]   [Full Text] [Related]  

  • 25. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.
    Namazi S; Kojuri J; Khalili A; Azarpira N
    Biochem Pharmacol; 2012 Apr; 83(7):903-8. PubMed ID: 22265638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel.
    Zabalza M; Subirana I; Sala J; Lluis-Ganella C; Lucas G; Tomás M; Masiá R; Marrugat J; Brugada R; Elosua R
    Heart; 2012 Jan; 98(2):100-8. PubMed ID: 21693476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
    Gurbel PA; Bergmeijer TO; Tantry US; ten Berg JM; Angiolillo DJ; James S; Lindahl TL; Svensson P; Jakubowski JA; Brown PB; Duvvuru S; Sundseth S; Walker JR; Small D; Moser BA; Winters KJ; Erlinge D
    Thromb Haemost; 2014 Sep; 112(3):589-97. PubMed ID: 25008027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.
    Price MJ; Tantry US; Gurbel PA
    Rev Cardiovasc Med; 2011; 12(1):1-12. PubMed ID: 21546883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
    Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
    Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
    Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A
    Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention.
    Bonello-Palot N; Armero S; Paganelli F; Mancini J; De Labriolle A; Bonello C; Lévy N; Maillard L; Barragan P; Dignat-George F; Camoin-Jau L; Bonello L
    Am J Cardiol; 2009 Dec; 104(11):1511-5. PubMed ID: 19932784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping.
    Alexopoulos D; Dimitropoulos G; Davlouros P; Xanthopoulou I; Kassimis G; Stavrou EF; Hahalis G; Athanassiadou A
    JACC Cardiovasc Interv; 2011 Apr; 4(4):403-10. PubMed ID: 21511219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polyunsaturated omega-3 fatty acids improve responsiveness to clopidogrel after percutaneous coronary intervention in patients with cytochrome P450 2C19 loss-of-function polymorphism.
    Gajos G; Zalewski J; Nessler J; Zmudka K; Undas A; Piwowarska W
    Kardiol Pol; 2012; 70(5):439-45. PubMed ID: 22623230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel.
    Jang JS; Cho KI; Jin HY; Seo JS; Yang TH; Kim DK; Kim DS; Seol SH; Kim DI; Kim BH; Park YH; Je HG; Jeong YH; Lee SW
    Am J Cardiol; 2012 Aug; 110(4):502-8. PubMed ID: 22591668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans.
    Oestreich JH; Best LG; Dobesh PP
    Am Heart J; 2014 Mar; 167(3):413-8. PubMed ID: 24576527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
    Maeda A; Ando H; Asai T; Ishiguro H; Umemoto N; Ohta M; Morishima M; Sumida A; Kobayashi T; Hosohata K; Ushijima K; Fujimura A
    Clin Pharmacol Ther; 2011 Feb; 89(2):229-33. PubMed ID: 21178986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods.
    Smock KJ; Saunders PJ; Rodgers GM; Johari V
    Am J Hematol; 2011 Dec; 86(12):1032-4. PubMed ID: 21812020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CYP2C19 genotype-guided antiplatelet therapy in a patient with clopidogrel resistance.
    Rai M; Seip RL; Gupta A; McKay RG; Hirst J; Thompson PD; Ruaño G
    Conn Med; 2012 May; 76(5):267-72. PubMed ID: 22685981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: is clinical testing helpful?
    Singh M; Shah T; Adigopula S; Molnar J; Ahmed A; Khosla S; Arora R
    Indian Heart J; 2012; 64(4):341-52. PubMed ID: 22929815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps?
    Gurbel PA; Roe MT; Jakubowski JA; Shah S; Erlinge D; Goodman SG; Huber K; Chan MY; Cornel JH; Tantry US; Ohman EM
    Thromb Haemost; 2012 Jul; 108(1):12-20. PubMed ID: 22627684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.